Xbrane Biopharma AB logo

XBRANE - Xbrane Biopharma AB Share Price

SEK76.2 -2.4  -3.1%

Last Trade - 3:07pm

Sector
Healthcare
Size
Small Cap
Market Cap £106.1m
Enterprise Value £99.4m
Revenue £n/a
Position in Universe 753rd / 1785
Bullish
Bearish
Unlock XBRANE Revenue
Momentum
Relative Strength (%)
1m +14.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -18.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.19 0.39 0.000 20.8 20.5 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Xbrane Biopharma AB revenues was not reported. Net loss increased 47% to SEK48.9M. Higher net loss reflects Biosimilars segment loss increase of 84% to SEK42.5M. Basic Earnings per Share excluding Extraordinary Items increased from -SEK4.99 to -SEK3.17.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for XBRANE
Graphical History

Revenue

XBRANE Revenue Unlock XBRANE Revenue

Net Income

XBRANE Net Income Unlock XBRANE Revenue

Normalised EPS

XBRANE Normalised EPS Unlock XBRANE Revenue

PE Ratio Range

XBRANE PE Ratio Range Unlock XBRANE Revenue

Dividend Yield Range

XBRANE Dividend Yield Range Unlock XBRANE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
XBRANE EPS Forecasts Unlock XBRANE Revenue
Profile Summary

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Public Since February 3, 2016
No. of Shareholders: 3,300
No. of Employees: 40
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 15,415,199
Free Float (0.0%)
Eligible for
ISAs
SIPPs
XBRANE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for XBRANE
Upcoming Events for XBRANE
Frequently Asked Questions for Xbrane Biopharma AB
What is the Xbrane Biopharma AB share price?

As of 3:07pm, shares in Xbrane Biopharma AB are trading at SEK76.2, giving the company a market capitalisation of £106.1m. This share price information is delayed by 15 minutes.

How has the Xbrane Biopharma AB share price performed this year?

Shares in Xbrane Biopharma AB are currently trading at SEK76.2 and the price has moved by 0.159k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Xbrane Biopharma AB price has moved by 0.172k% over the past year.

What are the analyst and broker recommendations for Xbrane Biopharma AB?

Of the analysts with advisory recommendations for Xbrane Biopharma AB, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Xbrane Biopharma AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Xbrane Biopharma AB next release its financial results?

Xbrane Biopharma AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Xbrane Biopharma AB dividend yield?

Xbrane Biopharma AB does not currently pay a dividend.

Does Xbrane Biopharma AB pay a dividend?

Xbrane Biopharma AB does not currently pay a dividend.

When does Xbrane Biopharma AB next pay dividends?

Xbrane Biopharma AB does not currently pay a dividend.

How do I buy Xbrane Biopharma AB shares?

To buy shares in Xbrane Biopharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Xbrane Biopharma AB?

Shares in Xbrane Biopharma AB are currently trading at SEK76.2, giving the company a market capitalisation of £106.1m.

Where are Xbrane Biopharma AB shares listed? Where are Xbrane Biopharma AB shares listed?

Here are the trading details for Xbrane Biopharma AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: XBRANE
What kind of share is Xbrane Biopharma AB?

Based on an overall assessment of its quality, value and momentum, Xbrane Biopharma AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Xbrane Biopharma AB share price forecast 2020?

Shares in Xbrane Biopharma AB are currently priced at SEK76.2. At that level they are trading at 23.66% premium to the analyst consensus target price of 0.00.

Analysts covering Xbrane Biopharma AB currently have a consensus Earnings Per Share (EPS) forecast of -12.16 for the next financial year.

How can I tell whether the Xbrane Biopharma AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xbrane Biopharma AB. Over the past six months, the relative strength of its shares against the market has been 96.06%. At the current price of SEK76.2, shares in Xbrane Biopharma AB are trading at 71.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Xbrane Biopharma AB PE Ratio?

We were not able to find PE ratio data for Xbrane Biopharma AB.

Who are the key directors of Xbrane Biopharma AB?

Xbrane Biopharma AB's management team is headed by:

Peter Edman - IND
Maris Hartmanis - IND
Karin Wingstrand - IND
Martin Amark - CEO
Siavash Bashiri - COO
David Vikstrom - CTO
Paolo Sarmientos - OTH
Giorgio Chirivi - IND
Susanna Helgesen - CFO
Dina Jurman - OTH
Anders Tullgren - CHM
Ivan Cohen-Tangui - IND
Eva Nilsagard - IND
Maria Edebrink - MGB
Anders Wallstrom - MGB
Xiaoli Hu - MGB
Who are the major shareholders of Xbrane Biopharma AB?

Here are the top five shareholders of Xbrane Biopharma AB based on the size of their shareholding:

Serendipity Group AB Corporation
Percentage owned: 14.63% (2.26m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 8.58% (1.32m shares)
STADA Arzneimittel AG Corporation
Percentage owned: 8.15% (1.26m shares)
Swedbank Robur Medica Mutual Fund
Percentage owned: 7.13% (1.10m shares)
TIN Fonder Investment Advisor
Percentage owned: 6.81% (1.05m shares)
Similar to XBRANE
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.